BACKGROUND: Circulating tumor cells (CTCs) can be identified in approximately 25% of nonmetastatic breast cancer patients, and data are emerging regarding their prognostic significance. We hypothesized that CTCs identified before resection of the primary tumor would predict worse outcomes in nonmetastatic breast cancer patients. STUDY DESIGN: We performed CTC enumerations on 509 patients with nonmetastatic breast cancer as part of an IRB-approved study. The CTCs (per 7.5 mL blood) were identified using the CellSearch System (Janssen). The presence of ≥1 CTC meeting morphologic criteria for malignancy was considered a positive result. Log-rank test and Cox regression analysis were applied to establish the association of CTCs with relapse-free and overall survival. RESULTS: Median follow-up was 48 months and mean age was 53 years. Fifty-nine percent of patients (299 of 509) had tumors larger than 2 cm, and 46% (234 of 509) had positive lymph nodes. One hundred sixty-six patients received neoadjuvant chemotherapy (NACT) before CTC assessment, and 343 patients were chemonaïve. One or more CTC was identified in 43 of 166 (26%) NACT treated patients, and in 81 of 343 (24%) chemonaïve patients. Circulating tumor cells were not associated with tumor size, grade, or lymph node status (p = NS). Detection of 1 or more CTCs predicted decreased relapse-free (log-rank p < 0.001, hazard ratio [HR] 2.72, 95% CI 1.57 to 4.72; p < 0.001) and overall survival (log-rank p = 0.02, HR 2.29, 95% CI 1.12 to 4.67; p = 0.03) at 48 months of follow-up. CONCLUSIONS: One or more CTCs identified before resection of the primary breast tumor predicted worse relapse-free and overall survival, irrespective of primary tumor size, grade, or lymph node positivity.
BACKGROUND: Circulating tumor cells (CTCs) can be identified in approximately 25% of nonmetastatic breast cancerpatients, and data are emerging regarding their prognostic significance. We hypothesized that CTCs identified before resection of the primary tumor would predict worse outcomes in nonmetastatic breast cancerpatients. STUDY DESIGN: We performed CTC enumerations on 509 patients with nonmetastatic breast cancer as part of an IRB-approved study. The CTCs (per 7.5 mL blood) were identified using the CellSearch System (Janssen). The presence of ≥1 CTC meeting morphologic criteria for malignancy was considered a positive result. Log-rank test and Cox regression analysis were applied to establish the association of CTCs with relapse-free and overall survival. RESULTS: Median follow-up was 48 months and mean age was 53 years. Fifty-nine percent of patients (299 of 509) had tumors larger than 2 cm, and 46% (234 of 509) had positive lymph nodes. One hundred sixty-six patients received neoadjuvant chemotherapy (NACT) before CTC assessment, and 343 patients were chemonaïve. One or more CTC was identified in 43 of 166 (26%) NACT treated patients, and in 81 of 343 (24%) chemonaïve patients. Circulating tumor cells were not associated with tumor size, grade, or lymph node status (p = NS). Detection of 1 or more CTCs predicted decreased relapse-free (log-rank p < 0.001, hazard ratio [HR] 2.72, 95% CI 1.57 to 4.72; p < 0.001) and overall survival (log-rank p = 0.02, HR 2.29, 95% CI 1.12 to 4.67; p = 0.03) at 48 months of follow-up. CONCLUSIONS: One or more CTCs identified before resection of the primary breast tumor predicted worse relapse-free and overall survival, irrespective of primary tumor size, grade, or lymph node positivity.
Authors: B Naume; E Borgen; K Beiske; T K Herstad; G Ravnås; A Renolen; S Trachsel; K Thrane-Steen; S Funderud; G Kvalheim Journal: J Hematother Date: 1997-04
Authors: Tanja Fehm; Oliver Hoffmann; Bahriye Aktas; Sven Becker; Erich F Solomayer; Diethelm Wallwiener; Rainer Kimmig; Sabine Kasimir-Bauer Journal: Breast Cancer Res Date: 2009-08-10 Impact factor: 6.466
Authors: F-C Bidard; C Mathiot; S Delaloge; E Brain; S Giachetti; P de Cremoux; M Marty; J-Y Pierga Journal: Ann Oncol Date: 2009-10-22 Impact factor: 32.976
Authors: Pia Wülfing; Julia Borchard; Horst Buerger; Stefan Heidl; Kurt S Zänker; Ludwig Kiesel; Burkhard Brandt Journal: Clin Cancer Res Date: 2006-03-15 Impact factor: 12.531
Authors: Jeffrey B Smerage; William E Barlow; Gabriel N Hortobagyi; Eric P Winer; Brian Leyland-Jones; Gordan Srkalovic; Sheela Tejwani; Anne F Schott; Mark A O'Rourke; Danika L Lew; Gerald V Doyle; Julie R Gralow; Robert B Livingston; Daniel F Hayes Journal: J Clin Oncol Date: 2014-06-02 Impact factor: 50.717
Authors: Brigitte Rack; Christian Schindlbeck; Julia Jückstock; Ulrich Andergassen; Philip Hepp; Thomas Zwingers; Thomas W P Friedl; Ralf Lorenz; Hans Tesch; Peter A Fasching; Tanja Fehm; Andreas Schneeweiss; Werner Lichtenegger; Matthias W Beckmann; Klaus Friese; Klaus Pantel; Wolfgang Janni Journal: J Natl Cancer Inst Date: 2014-05-15 Impact factor: 13.506
Authors: Chelain R Goodman; Brandon-Luke L Seagle; Thomas W P Friedl; Brigitte Rack; Krisztian Lato; Visnja Fink; Massimo Cristofanilli; Eric D Donnelly; Wolfgang Janni; Shohreh Shahabi; Jonathan B Strauss Journal: JAMA Oncol Date: 2018-08-09 Impact factor: 31.777
Authors: Michael G White; Andrew Lee; Diego Vicente; Carolyn Hall; Michael P Kim; Matthew H G Katz; Jeffrey E Lee; Naruhiko Ikoma; Anthony Lucci; Ching-Wei D Tzeng Journal: Ann Surg Oncol Date: 2021-01-07 Impact factor: 4.339
Authors: Levent Dizdar; Georg Fluegen; Guus van Dalum; Ellen Honisch; Rui P Neves; Dieter Niederacher; Hans Neubauer; Tanja Fehm; Alexander Rehders; Andreas Krieg; Wolfram T Knoefel; Nikolas H Stoecklein Journal: Mol Oncol Date: 2019-06-17 Impact factor: 6.603
Authors: Lucas Delmonico; Mauricio Augusto Silva Magalhães Costa; Romario José Gomes; Pâmella De Oliveira Vieira; Ana Beatriz Passos Da Silva; Marcia V Fournier; Luciano Rios Scherrer; Carolina Maria De Azevedo; Maria Helena Faria Ornellas; Gilda Alves Journal: Oncol Lett Date: 2020-02-10 Impact factor: 3.111
Authors: James Meehan; Mark Gray; Carlos Martínez-Pérez; Charlene Kay; Lisa Y Pang; Jennifer A Fraser; Amy V Poole; Ian H Kunkler; Simon P Langdon; David Argyle; Arran K Turnbull Journal: Front Oncol Date: 2020-04-24 Impact factor: 6.244